Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

Chan, S. L.Miksad, R.Cicin, I.Chen, Y.Klumpen, H. J.Kim, S.Lin, Z. Z.2024-06-122024-06-1220190923-75341569-8041https://hdl.handle.net/20.500.14551/26793European-Society-for-Medical-Oncology (ESMO) Asia Congress -- NOV 22-24, 2019 -- Singapore, SINGAPORE[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)Conference Object30Q1WOS:000503487700124